|
interesting new tx
(Preview)
development-program-at-the-international-liver-congress-2015-300062654.html
|
drummerman
|
0
|
1153
|
|
|
|
|
Forgotten History:The Hunt for Undiagnosed Patients with HCV
(Preview)
A long article on the history of and effort to get people in for testing and treatment. I found the article to be very telling of many of the situations we all found ourselves in at one time or another. The behavior, the stigma and the fight to get treated. I think you'll find this interesting. Healio is a g...
|
Tig
|
0
|
1013
|
|
|
|
|
FDA Grants Breakthrough Designations to Merck’s Hepatitis C Candidate
(Preview)
After rescinding breakthrough designation earlier this year, the FDA re-established two new designations for an oral combination tablet of grazoprevir/elbasvir for the treatment of chronic hepatitis C virus infection genotype 4 and genotype 1 with end stage renal disease on hemodialysis, ac...
|
Matt Chris
|
1
|
1624
|
|
|
|
|
Cipla announces the launch of generic drug Sofosbuvir in India, `Hepcvir`
(Preview)
India, Mumbai. March 25th, 2015 -Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week`s time.Full pres...
|
Cinnamon Girl
|
5
|
3062
|
|
|
|
|
Hepatitis C Competitive Landscape: The Holy Grail
(Preview)
An interesting op-ed with some current trends and results as researched by the author. The graphics and spreadsheet are quite informative.The Holy Grail
|
Tig
|
1
|
1095
|
|
|
|
|
FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
(Preview)
Bristol-Myers Squibb Company announced today (24 July, 2015) that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have...
|
Cinnamon Girl
|
3
|
1291
|
|
|
|
|
FDA approves `Technivie` for treatment of patients with Gen. 4
(Preview)
The U.S. Food and Drug Administration today (24th July, 2015) approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis)...
|
Cinnamon Girl
|
2
|
1503
|
|
|
|
|
July Newsletter HCV Advocate
(Preview)
FYI. Some more stuff about herbs. http://hcvadvocate.org/news/NewsUpdates_pdf/Advocate_2015/advocate0715.pdf
|
mallani
|
0
|
1093
|
|
|
|
|
At least 7 states limit patient costs for high-priced drugs
(Preview)
http://www.pbs.org/newshour/rundown/least-7-states-limit-patient-costs-high-priced-drugs/
|
RudiRoo
|
2
|
1303
|
|
|
|
|
Abbvie announces 100% SVR12 response in Turquoise-111 Phase 3b study results
(Preview)
NORTH CHICAGO, Ill., June 24,2015AbbVie today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b chronic hepatitis C virus infected adult patients with compensated liver cirrhosis. Pa...
|
Cinnamon Girl
|
1
|
1247
|
|
|
|
|
Daklinza (daclatasvir) recommended for use within NHS in Wales (UK)
(Preview)
All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) to be used, in combination with other medicinal products, as an option to treat eligible NHS patients with chronic hepatitis C and advanced liver disease. The All Wales Medicines Strategy Group (AWMSG) has recommended D...
|
Cinnamon Girl
|
4
|
1509
|
|
|
|
|
Healio - HCV Next and the ILC 2015
(Preview)
The information in this article is just part of the entire discussion and you will be asked to register (free) after accessing 6 articles. It's worth it imo. This particular article deals briefly with current therapies, RAV's, cirrhosis, transplantation, etc., from 4 experts in the field . I recom...
|
Tig
|
0
|
1028
|
|
|
|
|
Viekirax and Exviera (Viekira Pak) approved for use within NHS Scotland
(Preview)
The Scottish Medicines Consortium (SMC) has now approved Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) for use within NHS Scotland. Viekirax has been approved for use in combination with Exviera, with or without ribavirin, for the treatment of genotype 1 chronic he...
|
Cinnamon Girl
|
0
|
1214
|
|
|
|
|
NHS England agrees additional funding for new drugs `early access` scheme
(Preview)
NHS England agrees funding for new drug treatments for Hep C totalling almost a quarter of a billion pounds.In what will be the NHS` single largest investment in new treatments this year, NHS England has today (10 June 2015) announced it will be investing an estimated further £190 million in new cure...
|
Cinnamon Girl
|
0
|
955
|
|
|
|
|
Harvoni plus ribavirin increased adverse events but did not affect efficacy of Harvoni alone.
(Preview)
http://onlinelibrary.wiley.com/doi/10.1002/hep.27890/abstract;jsessionid=C90E1D60CDD7D4086DD149EA5CD4FF09.f01t02
|
RudiRoo
|
0
|
907
|
|
|
|
|
California woman sued insurer for Harvoni
(Preview)
http://www.latimes.com/business/la-fi-anthem-blue-cross-harvoni-lawsuit-20150518-story.html-- Edited by RudiRoo on Monday 8th of June 2015 11:10:13 PM
|
RudiRoo
|
0
|
1060
|
|
|
|
|
June 2015 - HCV Advocate Newsletter
(Preview)
http://hcvadvocate.org/news/newsLetter/2015/advocate0615.html#2
|
Cinnamon Girl
|
0
|
994
|
|
|
|
|
Gilead three drug investigational data released
(Preview)
Our new member Charly8 mentioned this new investigational drug from Gilead GS 9857. It is being combined with Sovaldi and their other investigational drug GS 5816. GS 9857 is a NS 3/4A PI. The data is from Phase 1and 2 studies. They are concentrating on both improved SVR rates and shortened treatment...
|
Tig
|
0
|
1189
|
|
|
|
|
HCV increases among younger IDUs in Appalachia
(Preview)
Sadly it seems that HCV is gaining ground among the <30 year old demographic in Appalachia. It's important for us to get the word out in our local community about this disease. There appears to be three issues at hand here, IV drug use and HCV/HIV. All potentially fatal. Our most important contribu...
|
Tig
|
0
|
1059
|
|
|
|
|
Sofosbuvir/Daclatasvir-High SVR at 4 weeks for GT1
(Preview)
http://dgnews.docguide.com/sofosbuvir-plus-daclatasvir-associated-high-sustained-virologic-response-4-weeks-patients-hepatitis?overlay=2&nl_ref=newsletter&pk_campaign=newsletterArticle pasted below in case above link does not workSofosbuvir Plus Daclata...
|
maddie
|
7
|
1937
|
|
|
|
|
Australia finally catches up
(Preview)
At last. Our PBAC has granted approval for PBS listing of Sovaldi, Harvoni and Daclatasvir. Our Minister of Health has to rubberstamp it, but this means this drugs will now be available for a nominal fee (maybe $20) for all Australians. Health care holders will get it free. The drugs will be available...
|
mallani
|
2
|
1244
|
|
|
|
|
Medicare Woe's
(Preview)
I was right, there is an article in Fierce Pharma about Medicare choking on the amount of Hep C applicants. Looks as if a limit is going to follow. $$$$$. Does anyone know what the treatment cost is for a 12 week course on Vikera-pac ? They talk a lot about Harvoni's cost, but what is the actual price for A...
|
bubble
|
1
|
1125
|
|
|
|
|
Could Allergy Drug Treat Hep C ?
(Preview)
Could An Allergy Drug Treat Hepatitis C? Just an interesting bit of the latest news on Hep C treatment. The drug is CCZ so if this link doesn't work just try CCZ and Hepatitis C. A drug that's been around for decades may help find a new solution for an expensive chronic disease http://time.com/381181...
|
suziq
|
1
|
1168
|
|
|
|
|
Just read this from CBS
(Preview)
http://www.cbsnews.com/news/cheap-allergy-drug-may-be-effective-for-hepatitis-c/
|
fourlocos
|
4
|
1737
|
|
|
|
|
April 2015 - HCV Advocate Newsletter
(Preview)
http://www.hcvadvocate.org/news/newsLetter/2015/advocate0415.html
|
Cinnamon Girl
|
2
|
1437
|
|
|
|
|
Gilead Warning from FDA
(Preview)
Its never good news when one of your drugs turns out to have caused the death of a patienteven if there are extenuating circumstancesand thats certainly the case for Gilead Sciences (GILD) today.Gilead SciencesGileads shares have dropped 1.9% to $100.36 at 10:30 a.m. after the biotech giant discl...
|
suziq
|
4
|
1986
|
|
|
|
|
Hep C BC presents the March 2015 release of Peppermint Patti's Hepatitis C FAQs version 10.0
(Preview)
March 18, 2015 from HCV New Drugs And Liver Health (148 pages) What happens when ordinary people make a difference? Remarkable things happen. Patricia Johnson is anything but ordinary, her work lives on in the now famous; Peppermint Pattis FAQs. http://hepcbc.ca/wp-content/uploads/2015/03...
|
Brownie
|
1
|
1811
|
|
|
|
|
Non-Invasive Biopies
(Preview)
While this article targets NASH rather than Hep C, the information is appropriate for all of us needing biopsies. I,also, was surprised at the number of people without Hep C that have or are in danger of developing cirrhosis. The prospect of having effective techniques of assessing liver damage w...
|
suziq
|
2
|
1578
|
|
|
|
|
One Percenters v. management tools
(Preview)
This was in the Washington Post today. I guess those of us who have benefited from the new medications are part of the 1 percenters. Those that haven't been fortunate enough to gain access to these "pricey specialty drugs" can blame it on "management tools".Prescription dru...
|
Gator Man
|
0
|
1264
|
|
|
|
|
March issue of HCV Advocate newsletter
(Preview)
Hi all, The March issue of the HCV Advocate newsletter is available. It's disappointing that the FDA will not be giving out any more Priority Reviews to HCV treatments. What about the Geno 3's? Also it's good to see that patients with a SVR can expect a 'normal' life span. Cheers. http://www.hcvadvo...
|
mallani
|
0
|
1204
|
|
|
